13 July 2022 : Clinical Research
Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland
Iwona Homa-Mlak1ACDEF*, Marcin Mazurek1BCEF, Aleksandra MajdanDOI: 10.12659/MSM.936534
Med Sci Monit 2022; 28:e936534
Table 3 Evaluation of diagnostic usefulness of calprotectin in detection of systemic lupus erythematosus (SLE) and specific clinical conditions by means of receiver operating characteristic (ROC) curve analysis.
| Variable | AUC [95% CI] | Sensitivity % | Specificity | Cut-off point | p |
|---|---|---|---|---|---|
| Study group vs control group | 0.720 (0.612–0.812) | 89.83 | 53.85 | >2.45 | 0.0001* |
| SLEDAIMild vs moderate and severe | 0.842 (0.724–0.924) | 100.00 | 82.46 | ≤2.37 | <0.0001* |
| SLEDAIMild and moderate vs severe | 0.504 (0.370–0.637) | 62.50 | 13.73 | ≤3.77 | 0.9789 |
| GFR [ml/min/1.73 m] | 0.508 (0.374–0.640) | 86.11 | 34.78 | ≤3.57 | 0.9253 |
| ESR [mm/h] | 0.544 (0.409–0.674) | 27.27 | 92.31 | >3.76 | 0.5664 |
| CRP [mg/l] | 0.676 (0.542–0.792) | 50.00 | 86.67 | ≤2.42 | 0.0668 |
| dsDNA | 0.565 (0.430–0.694) | 40.74 | 81.25 | >3.25 | 0.3994 |
| IgG [mg/dl] | 0.617 (0.393–0.809) | 33.33 | 100.00 | ≤1.64 | 0.6035 |
| IgA [mg/dl] | 0.716 (0.507–0.874) | 100.00 | 59.09 | >3.09 | 0.0296* |
| * Statistically significant results. AUC – area under the curve; CRP – C reactive protein; CI – confidence interval; dsDNA – double-stranded DNA; GFR – glomerular filtration rate; IgA – Immunoglobulin A; IgG – immunoglobulin G; ESR – erythrocyte sedimentation rate; SLEDAI – Systemic Lupus Erythematosus Disease Activity Index. | |||||






